Advanced Enzymes sees U.S. recovery signs, no timeline yet
Key highlights
- Advanced Enzymes said a U.S. turnaround could take one quarter, two quarters or longer after three to four weak quarters.
- Biocatalysis within Human Healthcare rose to Rs 6.6 crore in the second quarter from about Rs 4.5 crore in the first quarter.
- Rs 7.5 crore of previously deferred sales remained scheduled to carry into the next quarter.
- Advanced Enzymes retained its Rs 123 crore annual capex plan and spent about Rs 52 crore in the first half.
powered by IRIS

Advanced Enzyme Technologies is seeing early signs of a U.S. recovery after three to four quarters of difficult conditions, but management said the turnaround could take one quarter, two quarters or longer. Customer discussions, studies and product work are improving, although existing U.S. customers are not yet growing rapidly.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
What is driving Advanced Enzymes’ U.S. recovery expectation?
Advanced Enzymes attributes its improved U.S. outlook to research and development work, published papers, clinical studies and recent customer discussions. Management said it had returned from SupplySide West in Las Vegas, where it saw new traction and potential opportunities. The company did not disclose orders, revenue, customer wins or product conversions linked to the event.
The U.S. opportunity includes both already developed products and products that remain under development. Management said studies, papers and new applications continue even after a product has been developed, because the market is increasingly driven by supporting studies. Advanced Enzymes did not disclose the number of products in its U.S. pipeline, their validation stage or their expected sales contribution.
When will Advanced Enzymes’ U.S. market recover?
Advanced Enzymes cannot put a firm date on a U.S. recovery, and management said it could take one quarter, two quarters or longer. Management also said it expected the U.S. market to pick up toward the year-end. These are management expectations rather than formal U.S. revenue guidance.
The uncertain outlook follows what management described as three or four quarters, or possibly more, of conditions that were not conducive in the U.S. Management had earlier described dullness in the first two quarters amid global developments, while an analyst referred to previous tariff uncertainty. The call did not quantify the impact of tariffs, inflation, freight costs or any other external factor on U.S. revenue.
Are Advanced Enzymes’ existing U.S. customers growing again?
Advanced Enzymes said its existing U.S. customers are not yet growing rapidly, so the expected recovery does not depend solely on a rebound in its current customer base. Management said it is adding customers in different areas while developing products and applications. That approach combines new-customer additions with evidence-backed product positioning.
Advanced Enzymes did not comment on whether comparable companies are growing in the U.S., so the transcript does not establish whether the weakness is company-specific or industry-wide. Management also corrected an investor’s reference to DSM, saying DSM is a U.S. competitor rather than a direct customer relationship. Its disclosed response is to widen its customer base and applications rather than rely on a named customer’s recovery.
Which Advanced Enzymes businesses are growing outside the U.S.?
Advanced Enzymes said Food, animal feed and Biocatalysis are contributing to growth while U.S. demand remains uncertain. Management described Food and animal feed growth as robust and said Biocatalysis was picking up. It also reported positive trends in Europe and Asia, where it is adding customers, including some global players.
Biocatalysis within Human Healthcare increased to Rs 6.6 crore in the second quarter from about Rs 4.5 crore in the first quarter, based on an analyst’s comparison that management confirmed. Management said most Human Healthcare growth was coming from Biocatalysis and expected further recovery in Pharma and active pharmaceutical ingredient, or API, demand toward the year-end. The call did not disclose total Human Healthcare revenue, so Biocatalysis’ segment share cannot be calculated.
New products are also contributing to growth, although Advanced Enzymes does not separately report their revenue. When asked about new-product tracking, management estimated that roughly 7% to 8% of revenue comes from new products. For Animal Healthcare, Food Processing and Specialized Manufacturing, management cited wider customer reach, new products and entry into different geographies as growth mechanisms.
Got a follow-up? Ask IRIS
What operating factors could affect Advanced Enzymes’ outlook?
Advanced Enzymes is aiming for lower double-digit revenue growth overall, but management did not provide a quarterly, segment-specific or U.S.-specific target. Sales deferrals remain a timing factor: of Rs 10 crore deferred in the prior quarter, Rs 2.5 crore was recovered on a net basis in the latest quarter, leaving Rs 7.5 crore to carry into the next quarter. Management said deferrals were also elevated in the latest quarter.
Management reiterated an earnings before interest, tax, depreciation and amortisation, or EBITDA, framework of 30% to 32%, rather than confirming an Rs 70 crore quarterly EBITDA run rate. Employee costs declined to Rs 40 crore in the second quarter from Rs 45 crore in the first quarter. The finance executive attributed the movement to about Rs 1 crore of increment-provision reversal, employee stock-option reversals for departing staff and lower U.S. payroll from some headcount changes.
Advanced Enzymes retained its Rs 123 crore annual capital-expenditure plan, including research and development and maintenance spending, and said it had spent about Rs 52 crore in the first half. The company also said cash after the share buyback was roughly Rs 610 crore, excluding internal accruals generated during October. Management did not link either the capital-spending plan or cash balance to a specific U.S. recovery programme.
How does Advanced Enzymes’ broader growth plan support the U.S. outlook?
Advanced Enzymes said it has several growth areas across geographies rather than one single source of expansion. Management cited India, Asia, Food, animal feed and Biocatalysis as businesses and markets contributing to growth, while expecting the U.S. to add to that growth if its turnaround takes hold. This leaves the U.S. as a potential additional contributor rather than the only stated driver.
Specialized Manufacturing is one such diversification area, producing effervescent tablets and orally disintegrating tablets for cosmetics, pharmaceuticals, nutrition and animal feed. Management said its work there includes different delivery systems, including for feed applications. Separately, it said SciTech’s customer base had become wider after production efficiencies, added shift working and higher capacity utilisation improved output.
Conclusion
Advanced Enzymes has identified early U.S. recovery signals, but the evidence remains qualitative because management has not reported U.S. orders, revenue growth or a fixed turnaround date. Its three-to-four-quarter period of U.S. weakness contrasts with reported momentum in Food, animal feed and Biocatalysis, including the increase in Biocatalysis revenue to Rs 6.6 crore from about Rs 4.5 crore quarter on quarter.
The next points to watch are whether the expected year-end improvement in U.S. and Pharma/API demand materialises, whether Rs 7.5 crore of deferred sales moves into the next quarter, and progress on the Rs 123 crore capital-expenditure plan after Rs 52 crore was spent in the first half. Management said it would complete budgeting for the following financial year in February and March, when it may provide additional guidance.


